Methaqualone

Summary

Methaqualone (CHEMBL282052) is an approved small-molecule GABA agonist (ATC N05CM01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CM01 (+1 more)
• Chemistry: 250.29 Da · C16H14N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL282052
Name	Methaqualone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6292
ChEBI	CHEBI:6821
ATC	N05CM01, N05CX02
Molecular formula	C16H14N2O
Molecular weight	250.29
InChIKey	JEYCTXHKTXCGPB-UHFFFAOYSA-N

SMILES: CC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C

IUPAC name: 2-methyl-3-(2-methylphenyl)quinazolin-4-one

ChEBI definition: A member of the class of quinazolines that is quinazolin-4-one substituted at positions 2 and 3 by methyl and o-tolyl groups respectively. A depressant that increases the activity of the GABA receptors in the brain and nervous system, it is used as a sedative and hypnotic medication. It became popular as a recreational drug and club drug in the late 1960s and 1970s.

Pharmacological roles (ChEBI): GABA agonist, sedative.

Also known as: CI-705, CN 38703, CN-38703, Metacualona, Methaqualone, Methaqualoneinone, Metolquizolone, NSC-111388, NSC-126877, NSC-631628, QZ-2, R-148

Parent form; salt/anhydrous children: CHEMBL2106829

Patent coverage: 4,574 distinct patent families (14,678 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 14,348 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, Prelamin-A/C, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.5	Potency	316.2	nM	CHEMBL_ACT_3626756

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).